1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. BARINTHUS BIOTHERAPEUTICS PLC. - ADR

Barinthus Biotherapeutics Plc. - ADR

XNAS: BRNS

Download real time

1.05 0.00 (0.00%)

74.76% Fall from 52W High

6,423 XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
11S
6W
1O
1T
42.4

Market Cap

Below industry Median
-0.7

PE TTM

Negative PE TTM
0

PEG TTM

0.3

Price to Book

Low in industry
0.0

Beta 1Year

Very Low volatility


Insider Trading disclosures for Barinthus Biotherapeutics Plc. - ADR

The latest disclosure was made by William J. Enright in Barinthus Biotherapeutics Plc. - ADR where a trade of 600,000 Share Option (Right to Buy) done was reported to US exchanges on Feb. 3, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
William J. Enright Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 600,000 600,000 - - Share Option (Right to Buy)
Graham Griffiths Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 200,000 200,000 - - Share Option (Right to Buy)
Gemma Brown Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 160,000 160,000 - - Share Option (Right to Buy)
Leon Hooftman Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 140,000 140,000 - - Share Option (Right to Buy)
Leon Hooftman Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jun 2024 195,166 195,166 - - Share Option (Right to Buy)
Karen A. Dawes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
Anne M. Phillips Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
Robin Wright Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
Alex Hammacher Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
Pierre A. Morgon Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
Joseph C.F. Scheeren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 May 2024 19,516 19,516 - - Share Option (Right to Buy)
William J. Enright Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2024 443,981 443,981 - - Share Option (Right to Buy)
Graham Griffiths Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2024 96,500 96,500 - - Share Option (Right to Buy)
Gemma Brown Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2024 193,000 193,000 - - Share Option (Right to Buy)
Nadege Pelletier Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2024 105,000 105,000 - - Share Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters